NICE backs AZ’ Calquence for chronic lymphocytic leukaemia
The recommendations are positive for a select population of patients with CLL
Read More
Tag: acalabrutinib
Calquence shows long-term efficacy and tolerability in MCL
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with AstraZeneca’s Calquence remained progression free for a median of 22 months
Read More
Eleven medicines backed for EU approval
Recommendations include the first antibody-drug conjugate for multiple myeloma patients with limited treatment options
Read More
AZ’ Calquence shows promise for COVID-19
Improved markers of inflammation and reduced oxygen requirements were seen in most patients
Read More
AZ to test Calquence for COVID-19
The moves follows ‘strong scientific evidence’ indicating the role of the BTK pathway in the production of inflammatory cytokines
Read More
AZ’ Calquence boosts PFS in CLL patients
The drug demonstrates “remarkable efficacy”, says AZ’ José Baselga
Read More
AZ’ Calquence granted US Breakthrough Therapy Designation
The drug has been approved for chronic lymphocytic leukaemia.
Read More
AZ’ Calquence shows PFS benefit in CLL patients
A new filing for the drug as a treatment for relapsed or refractory chronic lymphocytic leukaemia is expected later this year
Read More
AZ’ Calquence trial to stop early after hitting endpoints
The drug was found to significantly increase the time patients live without disease progression.
Read More
FDA approves AstraZeneca’s Calquence
AstraZeneca’s Calquence has been given a speedy green light in the US as a treatment for adults with mantle cell lymphoma.
Read More
Priority review and breakthrough status for AZ’ acalabrutinib
AstraZeneca and group member Acerta Pharma say acalabrutinib is being given a priority review by the US Food and Drug Administration for mantle cell lymphoma (MCL), hot on the heels of it having been assigned a breakthrough designation by the regulator.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
